Acquisition of resistance to ceftazidime-avibactam during infection treatment in Pseudomonas aeruginosa through D179Y mutation in one of two blaKPC-2 gene copies without losing carbapenem resistance
Ceftazidime/Avibactam (CAZ/AVI) is frequently used to treat KPC-producing Pseudomonas aeruginosa (KPC-PA) and Enterobacterales. CAZ/AVI resistance is driven by several mechanisms. In P. aeruginosa this mainly occurs through alteration of AmpC, porins, and/or efflux pump overexpression, whereas in En...
| Auteurs principaux: | , , , , , , , |
|---|---|
| Format: | Article |
| Langue: | English |
| Publié: |
Frontiers Media S.A.
2022-09-01
|
| Collection: | Frontiers in Cellular and Infection Microbiology |
| Sujets: | |
| Accès en ligne: | https://www.frontiersin.org/articles/10.3389/fcimb.2022.981792/full |